La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Alcon Gestion

Gestion contrôle des critères 3/4

Le PDG Alcon's est David Endicott, nommé en Jul2018, a un mandat de 6.08 ans. La rémunération annuelle totale est $ 12.33M, composée du salaire de 10.7% et des bonus 89.3%, y compris les actions et options de la société. détient directement 0.047% des actions de la société, d'une valeur de CHF 19.32M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.3 ans et 5.6 ans.

Informations clés

David Endicott

Directeur général

US$12.3m

Rémunération totale

Pourcentage du salaire du PDG	10.7%
Durée du mandat du directeur général	6.1yrs
Propriété du PDG	0.05%
Durée moyenne d'occupation des postes de direction	5.3yrs
Durée moyenne du mandat des membres du conseil d'administration	5.6yrs

Mises à jour récentes de la gestion

Recent updates

Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Feb 15

Alcon Inc.'s (VTX:ALC) Business Is Yet to Catch Up With Its Share Price

Dec 22

Returns On Capital Are Showing Encouraging Signs At Alcon (VTX:ALC)

Dec 04

Calculating The Fair Value Of Alcon Inc. (VTX:ALC)

Nov 08

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Oct 18

Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger

Aug 25

A Look At The Fair Value Of Alcon Inc. (VTX:ALC)

Aug 10

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Jul 05

Investors Will Want Alcon's (VTX:ALC) Growth In ROCE To Persist

May 12

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Apr 03

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Feb 03

Returns Are Gaining Momentum At Alcon (VTX:ALC)

Jan 19

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Dec 18

Do Alcon's (VTX:ALC) Earnings Warrant Your Attention?

Nov 02

Alcon's (VTX:ALC) Returns On Capital Are Heading Higher

Sep 30

We Think Alcon (VTX:ALC) Can Stay On Top Of Its Debt

Sep 11

With Alcon Inc. (VTX:ALC) It Looks Like You'll Get What You Pay For

Aug 26

These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well

Jun 10

Alcon (VTX:ALC) Is Experiencing Growth In Returns On Capital

May 20

There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital

Feb 13

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Dec 28

We Like These Underlying Return On Capital Trends At Alcon (VTX:ALC)

Oct 26

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Sep 15

Alcon's (VTX:ALC) Robust Earnings Are Supported By Other Strong Factors

Aug 24

Analyse de la rémunération des PDG

Comment la rémunération de David Endicott a-t-elle évolué par rapport aux bénéfices de Alcon?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$12m	US$1m	US$974m
Sep 30 2023	n/a	n/a	US$450m
Jun 30 2023	n/a	n/a	US$362m
Mar 31 2023	n/a	n/a	US$341m
Dec 31 2022	US$10m	US$1m	US$335m
Sep 30 2022	n/a	n/a	US$571m
Jun 30 2022	n/a	n/a	US$457m
Mar 31 2022	n/a	n/a	US$460m
Dec 31 2021	US$11m	US$1m	US$376m
Sep 30 2021	n/a	n/a	US$332m
Jun 30 2021	n/a	n/a	US$183m
Mar 31 2021	n/a	n/a	-US$390m
Dec 31 2020	US$8m	US$1m	-US$531m
Sep 30 2020	n/a	n/a	-US$717m
Jun 30 2020	n/a	n/a	-US$636m
Mar 31 2020	n/a	n/a	-US$604m
Dec 31 2019	US$7m	US$1m	-US$656m

Rémunération vs marché: La rémunération totale de David ($USD 12.33M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Swiss ($USD 4.90M ).

Rémunération et revenus: La rémunération de David a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

David Endicott (59 yo)

6.1yrs

Titularisation

US$12,325,391

Compensation

Mr. David J. Endicott is President and Chief Executive Officer at Aerie Pharmaceuticals, Inc. since November 21, 2022. He had been the Chief Executive Officer of Alcon, Inc. since July 1, 2018. He is the C...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
F. Ball	Executive Chairman	5.6yrs	US$1.17m	0.011% $ 4.6m
David Endicott	CEO & Director	6.1yrs	US$12.33m	0.047% $ 19.3m
Arthur Cummings	Executive Director	no data	US$284.68k	0.0012% $ 478.4k
Timothy Stonesifer	Chief Financial Officer	5.3yrs	pas de données	0.020% $ 8.0m
Margaret Buckley	Chief Accounting Officer	no data	pas de données	pas de données
Franck Leveiller	Senior VP	2.2yrs	pas de données	pas de données
Sue-Jean Lin	Senior VP and Chief Information & Transformation Officer	no data	pas de données	0.0097% $ 4.0m
Royce Bedward	Senior VP	no data	pas de données	pas de données
Kimberly Martin	Senior VP	4.1yrs	pas de données	pas de données
Laurent Attias	Head of Corporate Development	no data	pas de données	0.0040% $ 1.6m
Leon Sergio Fraustro	President of North America	9yrs	pas de données	0.0043% $ 1.7m
Ed McGough	Senior VP and Head of Global Manufacturing & Technical Operations	no data	US$2.03m	pas de données

5.3yrs

Durée moyenne de l'emploi

58.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de ALC est chevronnée et expérimentée (ancienneté moyenne 5.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
F. Ball	Executive Chairman	5.6yrs	US$1.17m	0.011% $ 4.6m
David Endicott	CEO & Director	5.6yrs	US$12.33m	0.047% $ 19.3m
Arthur Cummings	Executive Director	5.6yrs	US$284.68k	0.0012% $ 478.4k
Karen May	Independent Director	5.6yrs	US$325.52k	0.0052% $ 2.1m
D. Grossman	Independent Vice Chair	5.6yrs	US$361.69k	0.0031% $ 1.3m
Thomas Glanzmann	Independent Director	5.6yrs	US$352.98k	0.0041% $ 1.7m
Dieter Spälti	Independent Director	5.6yrs	US$236.83k	0.0049% $ 2.0m
Scott Maw	Independent Director	5.6yrs	US$333.87k	0.0031% $ 1.2m
Lynn Bleil	Independent Director	5.6yrs	US$296.31k	0.0019% $ 797.3k
Ines Pöschel	Independent Director	5.6yrs	US$293.86k	0.0021% $ 866.8k
RaQuel Bono	Independent Director	2.3yrs	US$256.66k	0.00057% $ 233.1k

5.6yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ALC sont considérés comme expérimentés (ancienneté moyenne 5.6 ans).

Alcon Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Alcon Inc. Announces Executive Changes, Effective September 1, 2024

Alcon Announces Management Changes

President of North America notifies of intention to sell stock

Alcon Inc., Annual General Meeting, May 08, 2024

Head of Corporate Development notifies of intention to sell stock

Alcon Inc., Annual General Meeting, May 05, 2023

Recent updates

Alcon Inc. Announces Executive Changes, Effective September 1, 2024

Now 24% undervalued

Investor Optimism Abounds Alcon Inc. (VTX:ALC) But Growth Is Lacking

A Look At The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

Should You Be Adding Alcon (VTX:ALC) To Your Watchlist Today?

Alcon's (VTX:ALC) Returns On Capital Are Heading Higher

These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well

First quarter 2024 earnings: EPS exceeds analyst expectations

Upcoming dividend of CHF0.24 per share

Alcon Inc. Approves Gross Dividend

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Dividend of CHF0.24 announced

Alcon Inc.'s (VTX:ALC) Shareholders Might Be Looking For Exit

Alcon Announces Management Changes

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

President of North America notifies of intention to sell stock

Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc.'s (VTX:ALC) Business Is Yet to Catch Up With Its Share Price

Returns On Capital Are Showing Encouraging Signs At Alcon (VTX:ALC)

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Calculating The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

A Look At The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Head of Corporate Development notifies of intention to sell stock

Investors Will Want Alcon's (VTX:ALC) Growth In ROCE To Persist

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.21 per share at 0.3% yield

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Returns Are Gaining Momentum At Alcon (VTX:ALC)

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Now 20% undervalued

Alcon Inc. Updates Earnings Guidance for the Year 2022

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Do Alcon's (VTX:ALC) Earnings Warrant Your Attention?

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon's (VTX:ALC) Returns On Capital Are Heading Higher

We Think Alcon (VTX:ALC) Can Stay On Top Of Its Debt

With Alcon Inc. (VTX:ALC) It Looks Like You'll Get What You Pay For

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations

Alcon Inc. Revises Revenue Guidance for 2022

These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.